Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis

Pharmacogenetics and Genomics · Published 2025-02-12 · DOI 10.1097/fpc.0000000000000562

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1097/fpc.0000000000000562

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications · British Journal of Clinical Pharmacology · 2026 · Cites or is cited by this article
• Updated analysis of the pharmacogenomics of pediatric bronchodilator response · Pharmacogenetics and Genomics · 2024 · Same journal
• Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation · Pharmacogenetics and Genomics · 2025 · Same journal
• Pharmacogenomics of commonly used intravenous anesthetics · Pharmacogenetics and Genomics · 2025 · Same journal
• Application of risk priority number of failure mode and effects analysis to drug–variant pairs for severe cutaneous adverse reactions in Korean and American populations · Pharmacogenetics and Genomics · 2026 · Same journal
• Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity · Pharmacogenetics and Genomics · 2025 · Same journal
• Impact of CYP3A5 genotype on tacrolimus pharmacokinetics and clinical outcomes in pediatric patients with Henoch–Schönlein purpura nephritis · Pharmacogenetics and Genomics · 2026 · Same journal
• Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma · Pharmacogenetics and Genomics · 2024 · Same journal
• Association of estrogen and progesterone receptor polymorphisms with idiopathic thin endometrium · Pharmacogenetics and Genomics · 2025 · Same journal
• No interaction between genetic variants and DNA methylation of the ferrochelatase gene in relation to antituberculosis drug-induced liver injury · Pharmacogenetics and Genomics · 2025 · Same journal